Contact

Research Submission to Inform Medicare Drug Price Negotiation, IPAY 2027

Martin MJ, Kesselheim AS, Rome BN - Centers for Medicare and Medicaid Services (CMS)

  • Policy Interactions
| March 2025
  • Price, Value, and Access
  • Regulation and Clinical Evidence

Summary:

PORTAL submits summaries of peer-reviewed research to inform CMS’s evidence-based assessment of drugs selected for Medicare price negotiation in Initial Price Applicability Year (IPAY) 2027, including Trelegy Ellipta, Breo Ellipta, Ozempic/Rybelsus/Wegovy, Pomalyst, Xtandi, and Calquence.

VIEW SOURCE
An icon of a bill representing government policy.

LEARN MORE

BROWSE POLICY INTERACTIONS

Recent Work from PORTAL

Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing

Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics

  • Research Publications
| November 2026
  • Price, Value, and Access
View Source
Talk bubble graphics representing commentary and opinion.

How Congress Can Fix Expert Advisory Committees

Daval CJR, Kesselheim AS - STAT

  • Commentary & Opinion
| October 2026
  • Regulation and Clinical Evidence
View Source
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Coverage and Costs for Medications After Medicare Price Negotiation

Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine

  • Research Publications
| October 2026
  • Price, Value, and Access
View Source
VIEW MORE

Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115

©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.